Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
Spyre Therapeutics commenced an underwritten public offering of its common stock, with underwriters holding a 30-day option for an additional 15% of shares offered. Size and pricing were not disclosed; the deal is being run by Jefferies, TD Cowen, Leerink Partners and Stifel, with LifeSci Capital as passive bookrunner.
Key figures
- Underwriter option
- 30-day option for additional 15% of shares offered
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.